赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300485 赛升药业

已收盘 07-05 15:00:00

{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":6.27,"timestamp":1720162995000,"preClose":5.98,"halted":0,"volume":3921537,"delay":0,"floatShares":274000000,"shares":482000000,"eps":-0.1838,"marketStatus":"已收盘","marketStatusCode":5,"change":0.29,"latestTime":"07-05 15:00:00","open":5.98,"high":6.29,"low":5.88,"amount":24033900,"amplitude":0.0686,"askPrice":6.27,"askSize":517,"bidPrice":6.26,"bidSize":99,"shortable":0,"etf":0,"ttmEps":-0.1838,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720402200000},"adr":0,"adjPreClose":5.98,"symbolType":"stock","openAndCloseTimeList":[[1720143000000,1720150200000],[1720155600000,1720162800000]],"highLimit":6.58,"lowLimit":5.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"pbRate":0.89,"roa":"--","roe":"--","epsLYR":0.21,"committee":-0.701445,"marketValue":3020000000,"floatMarketCap":1717000000,"peRate":-34.113167,"changeRate":0.0485,"turnoverRate":0.0143,"status":0},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2448109627","title":"小儿豉翘清热颗粒等10款药被重点监控，涉济川药业、赛升药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2448109627","media":"新京报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448109627?lang=zh_cn&edition=full","pubTime":"2024-07-03 19:33","pubTimestamp":1720006380,"startTime":"0","endTime":"0","summary":"以小儿豉翘清热颗粒为例，该药为济川药业独家品种，主治小儿风热感冒。据米内网数据统计，2023年上半年，小儿豉翘清热颗粒在全国公立医院儿科感冒用中成药市场占比46.52%，排名第一。就旗下小儿豉翘清热颗粒被重点监控是否会影响销售等，记者向济川药业发去采访提纲，截至发稿暂未获对方回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703193410af906113&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703193410af906113&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0077","BK0012","BK0046","BK0239","BK0188","600566","BK0201","BK0187","300485"],"gpt_icon":0},{"id":"2443223578","title":"赛升药业（300485）6月13日主力资金净卖出138.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443223578","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443223578?lang=zh_cn&edition=full","pubTime":"2024-06-13 15:26","pubTimestamp":1718263568,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月13日收盘，赛升药业报收于6.48元，下跌2.7%，换手率0.85%，成交量2.34万手，成交额1521.06万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。赛升药业主营业务：注射针剂的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300023706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300485","BK0012","BK0028","BK0239"],"gpt_icon":0},{"id":"2442310182","title":"赛升药业获得发明专利授权：“利用气相色谱法检测安替安吉肽中残留溶剂的方法及应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2442310182","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442310182?lang=zh_cn&edition=full","pubTime":"2024-06-12 02:07","pubTimestamp":1718129223,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示赛升药业新获得一项发明专利授权，专利名为“利用气相色谱法检测安替安吉肽中残留溶剂的方法及应用”，专利申请号为CN202110796952.9，授权日为2024年6月11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200002633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","300485","BK0012"],"gpt_icon":0},{"id":"2441795585","title":"赛升药业：公司主营产品受市场和政策影响，销售量同比出现下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2441795585","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441795585?lang=zh_cn&edition=full","pubTime":"2024-06-06 17:04","pubTimestamp":1717664697,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业06月06日在投资者关系平台上答复投资者关心的问题。市场销售情况怎么样赛升药业董秘：您好，公司主导产品为生物生化药品，涉及心脑血管类疾病、 免疫性疾病（抗肿瘤）和神经系统疾病三大用药领域。目前，公司主营产品受市场和政策影响，销售量同比出现下滑。公司生产经营正常。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060600034401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300485","BK0012","BK0028","BK0046"],"gpt_icon":0},{"id":"2441761182","title":"赛升药业（300485）6月6日主力资金净卖出649.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441761182","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441761182?lang=zh_cn&edition=full","pubTime":"2024-06-06 15:35","pubTimestamp":1717659352,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月6日收盘，赛升药业报收于6.2元，下跌7.6%，换手率2.83%，成交量7.74万手，成交额4877.16万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。赛升药业主营业务：注射针剂的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060600026272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","300485","BK0046"],"gpt_icon":0},{"id":"2440069468","title":"赛升药业：公司始终守法合规经营，不存在您所述情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2440069468","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440069468?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:07","pubTimestamp":1717409250,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月03日在投资者关系平台上答复投资者关心的问题。投资者：公司的资金有没有被大股东占用？赛升药业董秘：您好，公司始终守法合规经营，不存在您所述情形。投资者：请问公司在传染病检测方面有没有相关技术？赛升药业董秘：您好，公司不涉及传染病检测方面相关业务。投资者：公司与国外医药公司有联合科研的规划吗？赛升药业董秘：您好，目前没有。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300023258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","300485","BK0046"],"gpt_icon":0},{"id":"2438806967","title":"赛升药业：对外股权投资要结合被投项目发展综合判断是否收回","url":"https://stock-news.laohu8.com/highlight/detail?id=2438806967","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438806967?lang=zh_cn&edition=full","pubTime":"2024-05-27 17:05","pubTimestamp":1716800723,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业05月27日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052700020468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0012","BK0046","BK0239"],"gpt_icon":0},{"id":"2437325642","title":"赛升药业(300485.SZ)拟10股派0.22元 于5月29日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2437325642","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437325642?lang=zh_cn&edition=full","pubTime":"2024-05-22 16:58","pubTimestamp":1716368297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司2023年年度权益分派拟：向全体股东每10股派发现金股利人民币0.22元(含税)。除权除息日为：2024年5月29日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","300485","BK0239","BK0028","BK0046"],"gpt_icon":0},{"id":"2435446340","title":"赛升药业：公司投资的基金未投资北京集成电路尖端芯片股权投资中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2435446340","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435446340?lang=zh_cn&edition=full","pubTime":"2024-05-13 18:06","pubTimestamp":1715594777,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)05月13日在投资者关系平台上答复投资者关心的问题。投资者：公司投资的基金投资的北京集成电路尖端芯片股权投资中心，都投资了哪些电路芯片公司？赛升药业董秘：您好，公司投资的基金未投资北京集成电路尖端芯片股权投资中心。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300020057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","159813","BK0046","159546","BK0239","300485","BK0012"],"gpt_icon":0},{"id":"2433717190","title":"赛升药业：公司具备基因工程和生物提取技术，可应用于合成生物学方面，目前公司不涉及该业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2433717190","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433717190?lang=zh_cn&edition=full","pubTime":"2024-05-08 17:05","pubTimestamp":1715159123,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业05月08日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800030261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0012","300485","BK0046"],"gpt_icon":0},{"id":"2433610713","title":"赛升药业（300485）5月8日主力资金净买入950.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433610713","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433610713?lang=zh_cn&edition=full","pubTime":"2024-05-08 15:21","pubTimestamp":1715152919,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月8日收盘，赛升药业报收于8.31元，上涨1.96%，换手率3.76%，成交量10.3万手，成交额8533.4万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。赛升药业主营业务：注射针剂的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800021288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300485","BK0012","BK0046"],"gpt_icon":0},{"id":"2431331260","title":"赛升药业：公司神经系统药物主要产品为赛典®单唾液酸四己糖神经节苷脂钠注射液（GM-1）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431331260","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431331260?lang=zh_cn&edition=full","pubTime":"2024-04-30 19:04","pubTimestamp":1714475090,"startTime":"0","endTime":"0","summary":"赛典单唾液酸四己糖神经节苷脂钠注射液用于治疗血管性或外伤性中枢神经系统损伤；帕金森氏病。2023年神经系统用药占公司营业收入比重为11.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000045854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","300485","BK0046"],"gpt_icon":0},{"id":"2430476057","title":"图解赛升药业一季报：第一季度单季净利润同比减23235.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430476057","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430476057?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:24","pubTimestamp":1714037094,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业2024年一季报显示，公司主营收入1.1亿元，同比下降17.46%；归母净利润-1.91亿元，同比下降23235.01%；扣非净利润1515.78万元，同比上升383.81%；负债率3.96%，投资收益-8297.34万元，财务费用-25.01万元，毛利率66.07%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500036455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2430742211","title":"赛升药业(300485.SZ)发布一季度业绩，净亏损1.91亿元，同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2430742211","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430742211?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:55","pubTimestamp":1714031737,"startTime":"0","endTime":"0","summary":"赛升药业(300485.SZ)发布2024年第一季度报告，该公司于期间实现营业收入...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0012","BK0028","BK0239","300485","BK0046"],"gpt_icon":0},{"id":"2420287799","title":"赛升药业(300485.SZ)：脱氧核苷酸钠注射液和盐酸精氨酸注射液中选药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2420287799","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420287799?lang=zh_cn&edition=full","pubTime":"2024-03-20 15:46","pubTimestamp":1710920760,"startTime":"0","endTime":"0","summary":"赛升药业公告，公司参与了京津冀“3+N”联盟药品集中采购和广州交易集团有限公司开展的易短缺和急抢救药品联盟集中带量采购工作，根据天津市医疗保障局发布的《关于做好第九批国家组织集采和京津冀“3+N”联盟药品集中采购结果执行工作的通知》和广州公共资源交易中心发布的《广州交易集团有限公司关于公布易短缺和急抢救药联盟集中带量采购中选/备选结果的通知》，公司产品脱氧核苷酸钠注射液和盐酸精氨酸注射液分别中选。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-20/doc-inanycms8326768.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-20/doc-inanycms8326768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0046","300485","BK0239","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","stockEarnings":[{"period":"1week","weight":-0.0308},{"period":"1month","weight":-0.1232},{"period":"3month","weight":-0.296},{"period":"6month","weight":-0.4199},{"period":"1year","weight":-0.4153},{"period":"ytd","weight":-0.4336}],"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","perCapita":"9271股","boardName":"医药制造业","registeredCapital":"48166万元","compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":-0.0432},{"period":"3month","weight":-0.0364},{"period":"6month","weight":0.0097},{"period":"1year","weight":-0.0823},{"period":"ytd","weight":-0.0058}],"survey":"　　北京赛升药业股份有限公司的主营业务为注射针剂的研发、生产及销售,主导产品为生物生化药品，涉及心脑血管类疾病、免疫性疾病(抗肿瘤)和神经系统疾病三大用药领域。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。公司及赛而生物发明专利“单唾液酸四己糖神经节苷脂的制备方法以及单唾液酸四己糖神经节苷脂钠注射液或冻干粉针”(专利号ZL200910085592.0)荣获第二十届中国专利优秀奖。纤溶酶注射液被评为2023年年度生化生物企业优秀品牌。","serverTime":1720171175734,"listedPrice":38.46,"stockholders":"29533人(较上一季度减少5.94%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}